Ginell Post
Concepts (257)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hodgkin Disease | 3 | 2019 | 49 | 1.190 |
Why?
| Plasma Cells | 4 | 2018 | 228 | 0.930 |
Why?
| Epidural Neoplasms | 1 | 2019 | 5 | 0.780 |
Why?
| ABO Blood-Group System | 1 | 2019 | 14 | 0.780 |
Why?
| Spinal Cord Compression | 1 | 2019 | 11 | 0.770 |
Why?
| von Willebrand Factor | 1 | 2019 | 55 | 0.750 |
Why?
| Pseudolymphoma | 1 | 2018 | 4 | 0.720 |
Why?
| Monocytes | 1 | 2019 | 159 | 0.720 |
Why?
| Scalp Dermatoses | 1 | 2018 | 7 | 0.720 |
Why?
| Tumor Microenvironment | 1 | 2019 | 144 | 0.700 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 3 | 2019 | 103 | 0.700 |
Why?
| Hematologic Neoplasms | 1 | 2019 | 89 | 0.700 |
Why?
| Pulmonary Embolism | 1 | 2019 | 106 | 0.690 |
Why?
| Antigens, CD | 1 | 2019 | 264 | 0.680 |
Why?
| Blood Coagulation Tests | 1 | 2017 | 24 | 0.670 |
Why?
| Optics and Photonics | 1 | 2017 | 14 | 0.670 |
Why?
| Endemic Diseases | 1 | 2017 | 24 | 0.670 |
Why?
| Diagnostic Tests, Routine | 1 | 2017 | 32 | 0.650 |
Why?
| Immunoglobulins | 1 | 2017 | 88 | 0.640 |
Why?
| Histoplasmosis | 1 | 2017 | 52 | 0.640 |
Why?
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 6 | 0.560 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2015 | 9 | 0.560 |
Why?
| Interleukin-6 | 1 | 2016 | 318 | 0.540 |
Why?
| Leukemoid Reaction | 1 | 2014 | 8 | 0.540 |
Why?
| Antifungal Agents | 1 | 2017 | 343 | 0.530 |
Why?
| Liposarcoma | 1 | 2014 | 26 | 0.530 |
Why?
| Muscle Neoplasms | 1 | 2014 | 23 | 0.530 |
Why?
| Receptors, Adrenergic, alpha-1 | 3 | 2003 | 14 | 0.520 |
Why?
| Neoplasms, Second Primary | 1 | 2014 | 73 | 0.510 |
Why?
| Sarcoma | 1 | 2014 | 77 | 0.490 |
Why?
| Neutrophils | 1 | 2014 | 163 | 0.490 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.470 |
Why?
| Fetomaternal Transfusion | 1 | 2012 | 2 | 0.470 |
Why?
| Plasma Exchange | 1 | 2012 | 34 | 0.450 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2012 | 27 | 0.450 |
Why?
| Humans | 29 | 2022 | 53051 | 0.430 |
Why?
| Cell Differentiation | 1 | 2015 | 758 | 0.430 |
Why?
| Liver | 1 | 2017 | 1263 | 0.410 |
Why?
| Graft vs Host Disease | 1 | 2011 | 86 | 0.400 |
Why?
| Myeloproliferative Disorders | 1 | 2010 | 25 | 0.400 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2011 | 274 | 0.390 |
Why?
| Multiple Myeloma | 4 | 2019 | 2757 | 0.370 |
Why?
| Bone Neoplasms | 1 | 2011 | 197 | 0.370 |
Why?
| Liver Transplantation | 1 | 2011 | 154 | 0.360 |
Why?
| Translocation, Genetic | 1 | 2010 | 290 | 0.340 |
Why?
| Phenotype | 2 | 2019 | 842 | 0.300 |
Why?
| Pancytopenia | 3 | 2011 | 39 | 0.290 |
Why?
| Immunohistochemistry | 3 | 2017 | 1143 | 0.270 |
Why?
| Lymphoma | 2 | 2018 | 62 | 0.270 |
Why?
| Guanine Nucleotide Exchange Factors | 2 | 2013 | 18 | 0.260 |
Why?
| Male | 12 | 2022 | 28342 | 0.250 |
Why?
| Female | 11 | 2022 | 28985 | 0.240 |
Why?
| Lymph Nodes | 2 | 2016 | 289 | 0.240 |
Why?
| Heterotrimeric GTP-Binding Proteins | 1 | 2002 | 7 | 0.240 |
Why?
| Focal Adhesions | 1 | 2002 | 14 | 0.240 |
Why?
| Peptide Hydrolases | 2 | 2014 | 70 | 0.240 |
Why?
| Receptors, Immunologic | 1 | 2002 | 38 | 0.240 |
Why?
| Macrophages | 2 | 2019 | 412 | 0.230 |
Why?
| Diagnosis, Differential | 3 | 2018 | 1185 | 0.230 |
Why?
| Rad52 DNA Repair and Recombination Protein | 1 | 2022 | 3 | 0.230 |
Why?
| Immunoglobulin Class Switching | 1 | 2022 | 7 | 0.230 |
Why?
| Immunoglobulin D | 1 | 2022 | 4 | 0.230 |
Why?
| Enzyme Activators | 1 | 2002 | 8 | 0.230 |
Why?
| Adrenergic alpha-Agonists | 1 | 2002 | 21 | 0.230 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2003 | 183 | 0.220 |
Why?
| Myocardium | 2 | 2003 | 468 | 0.220 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 84 | 0.220 |
Why?
| Biopsy | 2 | 2016 | 698 | 0.220 |
Why?
| Escherichia coli Proteins | 1 | 2002 | 100 | 0.210 |
Why?
| Middle Aged | 5 | 2019 | 13685 | 0.200 |
Why?
| Tissue Array Analysis | 1 | 2019 | 53 | 0.190 |
Why?
| Paraffin Embedding | 1 | 2019 | 59 | 0.190 |
Why?
| Sarcoma, Myeloid | 1 | 2019 | 23 | 0.190 |
Why?
| Glycosylation | 1 | 2019 | 107 | 0.190 |
Why?
| Bacterial Proteins | 2 | 2014 | 472 | 0.180 |
Why?
| Adolescent | 3 | 2019 | 6889 | 0.180 |
Why?
| Color | 1 | 2018 | 29 | 0.170 |
Why?
| Automation | 1 | 2018 | 23 | 0.170 |
Why?
| Lymphatic Vessels | 1 | 2018 | 45 | 0.170 |
Why?
| Aged, 80 and over | 2 | 2018 | 3642 | 0.170 |
Why?
| Partial Thromboplastin Time | 1 | 2017 | 12 | 0.170 |
Why?
| Prothrombin Time | 1 | 2017 | 20 | 0.170 |
Why?
| Immunophenotyping | 1 | 2018 | 129 | 0.170 |
Why?
| Failure to Thrive | 1 | 2017 | 23 | 0.170 |
Why?
| Histoplasma | 1 | 2017 | 27 | 0.170 |
Why?
| Myocytes, Cardiac | 2 | 2013 | 148 | 0.170 |
Why?
| Rare Diseases | 1 | 2017 | 42 | 0.160 |
Why?
| Clonal Evolution | 1 | 2018 | 59 | 0.160 |
Why?
| Endothelial Cells | 1 | 2019 | 294 | 0.160 |
Why?
| Vomiting | 1 | 2017 | 72 | 0.160 |
Why?
| Blood Coagulation | 1 | 2017 | 81 | 0.160 |
Why?
| Biopsy, Needle | 1 | 2017 | 205 | 0.160 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 201 | 0.150 |
Why?
| Gene Expression Regulation | 1 | 2002 | 1146 | 0.150 |
Why?
| Young Adult | 2 | 2019 | 4310 | 0.150 |
Why?
| Neoplasm, Residual | 1 | 2017 | 176 | 0.150 |
Why?
| Lung | 1 | 2019 | 490 | 0.150 |
Why?
| Bone Marrow | 1 | 2018 | 412 | 0.150 |
Why?
| Risk Assessment | 2 | 2017 | 1419 | 0.140 |
Why?
| V(D)J Recombination | 1 | 2015 | 4 | 0.140 |
Why?
| Algorithms | 1 | 2019 | 738 | 0.140 |
Why?
| Mice | 8 | 2022 | 6403 | 0.140 |
Why?
| Weight Loss | 1 | 2017 | 267 | 0.140 |
Why?
| Flow Cytometry | 1 | 2018 | 583 | 0.140 |
Why?
| Pyridines | 2 | 2008 | 144 | 0.130 |
Why?
| Fatal Outcome | 1 | 2014 | 235 | 0.130 |
Why?
| Neoplasm Metastasis | 2 | 2012 | 265 | 0.130 |
Why?
| Protein Kinases | 1 | 2014 | 95 | 0.120 |
Why?
| Cells, Cultured | 4 | 2013 | 1840 | 0.120 |
Why?
| Aged | 3 | 2019 | 10476 | 0.120 |
Why?
| Animals | 10 | 2022 | 14806 | 0.120 |
Why?
| Polymerase Chain Reaction | 1 | 2015 | 554 | 0.120 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 91 | 0.120 |
Why?
| Rh Isoimmunization | 1 | 2012 | 2 | 0.120 |
Why?
| Rho(D) Immune Globulin | 1 | 2012 | 4 | 0.120 |
Why?
| Transcription Factors | 2 | 2014 | 640 | 0.120 |
Why?
| Chromogranins | 1 | 2012 | 6 | 0.120 |
Why?
| Synaptophysin | 1 | 2012 | 9 | 0.120 |
Why?
| Pregnancy Complications, Hematologic | 1 | 2012 | 14 | 0.120 |
Why?
| Vimentin | 1 | 2012 | 30 | 0.110 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 173 | 0.110 |
Why?
| Virulence Factors | 1 | 2012 | 96 | 0.110 |
Why?
| Follow-Up Studies | 1 | 2017 | 2452 | 0.110 |
Why?
| Leukemia, Myelomonocytic, Chronic | 1 | 2011 | 18 | 0.110 |
Why?
| Antineoplastic Agents | 2 | 2012 | 1290 | 0.110 |
Why?
| Leukocytosis | 1 | 2011 | 14 | 0.110 |
Why?
| Chimerism | 1 | 2011 | 8 | 0.110 |
Why?
| Plateletpheresis | 1 | 2010 | 8 | 0.100 |
Why?
| Telomerase | 1 | 2010 | 30 | 0.100 |
Why?
| Blood Preservation | 1 | 2010 | 31 | 0.100 |
Why?
| Myelodysplastic Syndromes | 1 | 2011 | 85 | 0.100 |
Why?
| Chromosomes, Human, Pair 8 | 1 | 2010 | 17 | 0.100 |
Why?
| Infant | 2 | 2017 | 3699 | 0.100 |
Why?
| Keratinocytes | 1 | 2011 | 85 | 0.100 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2010 | 21 | 0.100 |
Why?
| Retrospective Studies | 2 | 2019 | 6079 | 0.100 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2010 | 22 | 0.100 |
Why?
| Blotting, Western | 2 | 2002 | 721 | 0.100 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2012 | 252 | 0.100 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2011 | 111 | 0.100 |
Why?
| Adult | 3 | 2019 | 14383 | 0.100 |
Why?
| Blood Proteins | 1 | 2010 | 104 | 0.100 |
Why?
| Anaphylaxis | 1 | 2010 | 71 | 0.100 |
Why?
| Bone Marrow Cells | 1 | 2011 | 245 | 0.100 |
Why?
| Neural Tube Defects | 1 | 2008 | 30 | 0.090 |
Why?
| Thoracic Wall | 1 | 2008 | 9 | 0.090 |
Why?
| Benzenesulfonates | 1 | 2008 | 13 | 0.090 |
Why?
| Copper | 1 | 2008 | 52 | 0.090 |
Why?
| Staphylococcus aureus | 1 | 2012 | 361 | 0.090 |
Why?
| Mice, Transgenic | 3 | 2013 | 729 | 0.090 |
Why?
| Nerve Sheath Neoplasms | 1 | 2008 | 24 | 0.090 |
Why?
| Neurilemmoma | 1 | 2008 | 28 | 0.090 |
Why?
| Treatment Outcome | 2 | 2017 | 5646 | 0.080 |
Why?
| Blood Platelets | 1 | 2010 | 306 | 0.080 |
Why?
| Skin | 1 | 2011 | 443 | 0.080 |
Why?
| Atherosclerosis | 1 | 2010 | 273 | 0.080 |
Why?
| Mice, Knockout | 3 | 2022 | 1006 | 0.080 |
Why?
| Rats | 3 | 2003 | 3596 | 0.080 |
Why?
| Inflammation | 1 | 2010 | 671 | 0.070 |
Why?
| Pregnancy | 1 | 2012 | 2432 | 0.070 |
Why?
| Isoenzymes | 2 | 2003 | 189 | 0.070 |
Why?
| Infant, Newborn | 1 | 2012 | 2773 | 0.070 |
Why?
| Animals, Newborn | 2 | 2003 | 400 | 0.060 |
Why?
| Uridine Triphosphate | 1 | 2003 | 15 | 0.060 |
Why?
| Heart | 2 | 2003 | 348 | 0.060 |
Why?
| Chromosome Aberrations | 2 | 2018 | 311 | 0.060 |
Why?
| Pertussis Toxin | 1 | 2002 | 11 | 0.060 |
Why?
| Catheter-Related Infections | 2 | 2014 | 57 | 0.060 |
Why?
| Biopolymers | 1 | 2002 | 18 | 0.060 |
Why?
| Receptors, Scavenger | 1 | 2002 | 30 | 0.060 |
Why?
| Macrophages, Peritoneal | 1 | 2002 | 38 | 0.060 |
Why?
| Virulence | 2 | 2014 | 195 | 0.060 |
Why?
| Scavenger Receptors, Class A | 1 | 2002 | 43 | 0.060 |
Why?
| Atrial Natriuretic Factor | 1 | 2002 | 27 | 0.060 |
Why?
| Adrenergic alpha-1 Receptor Agonists | 1 | 2002 | 3 | 0.060 |
Why?
| Cell Adhesion | 1 | 2002 | 188 | 0.060 |
Why?
| Thymidine | 1 | 2002 | 29 | 0.060 |
Why?
| Bacteremia | 2 | 2014 | 102 | 0.060 |
Why?
| Disease Models, Animal | 3 | 2014 | 1700 | 0.060 |
Why?
| Blotting, Northern | 1 | 2002 | 120 | 0.060 |
Why?
| Actins | 1 | 2002 | 140 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 39 | 0.060 |
Why?
| MAP Kinase Kinase 4 | 1 | 2002 | 33 | 0.060 |
Why?
| Primary Cell Culture | 1 | 2022 | 68 | 0.060 |
Why?
| Genes, Reporter | 1 | 2002 | 116 | 0.060 |
Why?
| Gene Knockdown Techniques | 1 | 2022 | 132 | 0.060 |
Why?
| Adenosine Triphosphate | 1 | 2003 | 235 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2002 | 146 | 0.050 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 101 | 0.050 |
Why?
| Recombination, Genetic | 1 | 2022 | 114 | 0.050 |
Why?
| Enzyme Activation | 1 | 2002 | 346 | 0.050 |
Why?
| Transfection | 1 | 2002 | 436 | 0.050 |
Why?
| B-Lymphocytes | 1 | 2022 | 187 | 0.050 |
Why?
| Rats, Sprague-Dawley | 2 | 2003 | 1810 | 0.050 |
Why?
| Methionine | 1 | 2002 | 143 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 370 | 0.050 |
Why?
| Imidazoles | 1 | 2002 | 153 | 0.050 |
Why?
| Repressor Proteins | 1 | 2002 | 171 | 0.050 |
Why?
| Phosphorylation | 1 | 2022 | 645 | 0.050 |
Why?
| Heart Ventricles | 1 | 2002 | 270 | 0.050 |
Why?
| Carrier Proteins | 1 | 2002 | 373 | 0.050 |
Why?
| Fibroblasts | 1 | 2002 | 380 | 0.050 |
Why?
| Cell Line | 1 | 2002 | 1226 | 0.050 |
Why?
| Promoter Regions, Genetic | 1 | 2002 | 562 | 0.050 |
Why?
| DNA-Binding Proteins | 1 | 2022 | 512 | 0.040 |
Why?
| Pathology, Molecular | 1 | 2018 | 23 | 0.040 |
Why?
| DNA | 1 | 2002 | 584 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 196 | 0.040 |
Why?
| Animals, Outbred Strains | 1 | 2012 | 16 | 0.030 |
Why?
| Daptomycin | 1 | 2012 | 39 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 278 | 0.030 |
Why?
| Prognosis | 1 | 2017 | 2105 | 0.030 |
Why?
| Karyotyping | 1 | 2011 | 99 | 0.030 |
Why?
| Cell Survival | 1 | 2013 | 695 | 0.030 |
Why?
| Isotonic Solutions | 1 | 2010 | 22 | 0.030 |
Why?
| Platelet Transfusion | 1 | 2010 | 34 | 0.030 |
Why?
| P-Selectin | 1 | 2010 | 45 | 0.030 |
Why?
| Receptors, LDL | 1 | 2010 | 76 | 0.030 |
Why?
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 17 | 0.030 |
Why?
| Sodium Chloride | 1 | 2010 | 68 | 0.030 |
Why?
| Platelet Aggregation | 1 | 2010 | 93 | 0.030 |
Why?
| Biofilms | 1 | 2012 | 206 | 0.030 |
Why?
| Platelet Activation | 1 | 2010 | 67 | 0.020 |
Why?
| Hypersensitivity | 1 | 2010 | 74 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2010 | 215 | 0.020 |
Why?
| Time Factors | 1 | 2017 | 3439 | 0.020 |
Why?
| Staphylococcal Infections | 1 | 2012 | 300 | 0.020 |
Why?
| Short Bowel Syndrome | 1 | 2008 | 17 | 0.020 |
Why?
| Parenteral Nutrition, Total | 1 | 2008 | 28 | 0.020 |
Why?
| NF-kappa B | 1 | 2010 | 345 | 0.020 |
Why?
| Phenylurea Compounds | 1 | 2008 | 15 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2010 | 214 | 0.020 |
Why?
| Coronary Vessels | 1 | 2010 | 202 | 0.020 |
Why?
| Enterocolitis, Necrotizing | 1 | 2008 | 34 | 0.020 |
Why?
| Niacinamide | 1 | 2008 | 25 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2010 | 443 | 0.020 |
Why?
| Radiography, Thoracic | 1 | 2008 | 70 | 0.020 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 794 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2008 | 217 | 0.020 |
Why?
| Brain Neoplasms | 1 | 2008 | 252 | 0.020 |
Why?
| Mutation | 1 | 2011 | 1432 | 0.020 |
Why?
| Adrenergic Agonists | 1 | 2003 | 6 | 0.020 |
Why?
| Purinergic P1 Receptor Antagonists | 1 | 2003 | 2 | 0.020 |
Why?
| Purinergic P2 Receptor Antagonists | 1 | 2003 | 7 | 0.020 |
Why?
| Phospholipase C beta | 1 | 2003 | 2 | 0.020 |
Why?
| Phospholipase C gamma | 1 | 2003 | 5 | 0.020 |
Why?
| Type C Phospholipases | 1 | 2003 | 17 | 0.020 |
Why?
| Phenylephrine | 1 | 2003 | 37 | 0.020 |
Why?
| Perfusion | 1 | 2003 | 43 | 0.020 |
Why?
| Hypertrophy | 1 | 2003 | 51 | 0.020 |
Why?
| Vasoconstriction | 1 | 2003 | 62 | 0.020 |
Why?
| Cyclic AMP | 1 | 2003 | 118 | 0.010 |
Why?
| Lung Neoplasms | 1 | 2008 | 599 | 0.010 |
Why?
| Aorta | 1 | 2003 | 183 | 0.010 |
Why?
| Electrocardiography | 1 | 2003 | 313 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2008 | 1724 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2003 | 1572 | 0.010 |
Why?
|
|
Post's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|